Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction

Science Translational Medicine

Volumn 8, Issue 330, 2016, Pages

  Wehmeyer, Corinna ^a   Frank, Svetlana ^a   Beckmann, Denise ^a   Böttcher, Martin ^b   Cromme, Christoph ^a   König, Ulrich ^a   Fennen, Michelle ^a   Held, Annelena ^a   Paruzel, Peter ^a   Hartmann, Christine ^a   Stratis, Athanasios ^a   Korb Pap, Adelheid ^a   Kamradt, Thomas ^b   Kramer, Ina ^c   Van Den Berg, Wim ^d   Kneissel, Michaela ^c   Pap, Thomas ^a   Dankbar, Berno ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE ISOMERASE; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; GLYCOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LRP6 PROTEIN, MOUSE; SOST PROTEIN, HUMAN; SOST PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETIC MARKER; INFLAMMATION; JOINT; METABOLISM; PATHOLOGY; SYNOVIUM; TRANSGENIC MOUSE;

AGED; ANIMALS; ARTHRITIS, RHEUMATOID; BETA CATENIN; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENETIC MARKERS; GLUCOSE-6-PHOSPHATE ISOMERASE; GLYCOPROTEINS; HUMANS; INFLAMMATION; INTERLEUKIN-1; JOINTS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MICE, TRANSGENIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961832342     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac4351     Document Type: Article

References (52)

1. L. C. Huber, O. Distler, I. Tarner, R. E. Gay, S. Gay, T. Pap, Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology 45, 669-675 (2006).
2. N. C. Walsh, T. N. Crotti, S. R. Goldring, E. M. Gravallese, Rheumatic diseases: The effects of inflammation on bone. Immunol. Rev. 208, 228-251 (2005).
3. U. Müller-Ladner, T. Pap, R. E. Gay, M. Neidhart, S. Gay, Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1, 102-110 (2005).
4. D. R. Bertolini, G. E. Nedwin, T. S. Bringman, D. D. Smith, G. R. Mundy, Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516-518 (1986).
5. K. Redlich, S. Hayer, R. Ricci, J.-P. David, M. Tohidast-Akrad, G. Kollias, G. Steiner, J. S. Smolen, E. F. Wagner, G. Schett, Osteoclasts are essential for TNF-A-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
6. D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M. S. Ominsky, D. Dwyer, A. Korb, J. Smolen, M. Hoffmann, C. Scheinecker, D. van der Heide, R. Landewe, D. Lacey, W. G. Richards, G. Schett, Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156-163 (2007).
7. J. J. Westendorf, R. A. Kahler, T. M. Schroeder, Wnt signaling in osteoblasts and bone diseases. Gene 341, 19-39 (2004).
8. C. Y. Logan, R. Nusse, The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810 (2004).
9. V. Krishnan, H. U. Bryant, O. A. MacDougald, Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202-1209 (2006).
10. D. A. Glass II, G. Karsenty, Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr. Top. Dev. Biol. 73, 43-84 (2006).
11. B. M. Gumbiner, Propagation and localization of Wnt signaling. Curr. Opin. Genet. Dev. 8, 430-435 (1998).
12. A. Wodarz, R. Nusse, Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14, 59-88 (1998).
13. F. Cong, L. Schweizer, H. Varmus, Wnt signals across the plasma membrane to activate the b-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 131, 5103-5115 (2004).
14. J. Bili?, Y.-L. Huang, G. Davidson, T. Zimmermann, C.-M. Cruciat, M. Bienz, C. Niehrs, Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 316, 1619-1622 (2007).
15. X. Li, Y. Zhang, H. Kang, W. Liu, P. Liu, J. Zhang, S. E. Harris, D. Wu, Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883-19887 (2005).
16. M. E. Brunkow, J. C. Gardner, J. Van Ness, B. W. Paeper, B. R. Kovacevich, S. Proll, J. E. Skonier, L. Zhao, P. J. Sabo, Y.-H. Fu, R. S. Alisch, L. Gillett, T. Colbert, P. Tacconi, D. Galas, H. Hamersma, P. Beighton, J. T. Mulligan, Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577-589 (2001).
17. W. Balemans, N. Patel, M. Ebeling, E. Van Hul, W. Wuyts, C. Lacza, M. Dioszegi, F. G. Dikkers, P. Hildering, P. J. Willems, J. B. G. M. Verheij, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91-97 (2002).
18. G. G. Loots, M. Kneissel, H. Keller, M. Baptist, J. Chang, N. M. Collette, D. Ovcharenko, I. Plajzer-Frick, E. M. Rubin, Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15, 928-935 (2005).
19. I. Kramer, G. G. Loots, A. Studer, H. Keller, M. Kneissel, Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res. 25, 178-189 (2010).
20. X. Li, M. S. Ominsky, Q.-T. Niu, N. Sun, B. Daugherty, D. D'Agostin, C. Kurahara, Y. Gao, J. Cao, J. Gong, F. Asuncion, M. Barrero, K. Warmington, D. Dwyer, M. Stolina, S. Morony, I. Sarosi, P. J. Kostenuik, D. L. Lacey, W. S. Simonet, H. Z. Ke, C. Paszty, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860-869 (2008).
21. X. Li, Q.-T. Niu, K. S. Warmington, F. J. Asuncion, D. Dwyer, M. Grisanti, C.-Y. Han, M. Stolina, M. J. Eschenberg, P. J. Kostenuik,W. S. Simonet, M. S. Ominsky, H. Z. Ke, Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 155, 4785-4797 (2014).
22. A. Roschger, P. Roschger, P. Keplingter, K. Klaushofer, S. Abdullah, M. Kneissel, F. Rauch, Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 66, 182-188 (2014).
23. L. Cui, H. Cheng, C. Song, C. Li, W. S. Simonet, H. Z. Ke, G. Li, Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J. Musculoskelet. Neuronal Interact. 13, 178-184 (2013).
24. R. R. Recker, C. T. Benson, T. Matsumoto, M. A. Bolognese, D. A. Robins, J. Alam, A. Y. Chiang, L. Hu, J. H. Krege, H. Sowa, B. H. Mitlak, S. L. Myers, A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 30, 216-224 2015.
25. M. R. McClung, A. Grauer, S. Boonen, M. A. Bolognese, J. P. Brown, A. Diez-Perez, B. L. Langdahl, J.-Y. Reginster, J. R. Zanchetta, S. M. Wasserman, L. Katz, J. Maddox, Y.-C. Yang, C. Libanati, H. G. Bone, Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412-420 (2014).
26. C. Vincent, D. M. Findlay, K. J.Welldon, A. R. Wijenayaka, T. S. Zheng, D. R. Haynes, N. L. Fazzalari, A. Evdokiou, G. J. Atkins, Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFa induce the mitogen-Activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res. 24, 1434-1449 (2009).
27. J. Keffer, L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, G. Kollias, Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
28. G. Schett, M. Tohidast-Akrad, J. S. Smolen, B. J. Schmid, C.-W. Steiner, P. Bitzan, P. Zenz, K. Redlich, Q. Xu, G. Steiner, Activation, differential localization, and regulation of the stressactivated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-Activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43, 2501-2512 (2000).
29. J. Zwerina, S. Hayer, K. Redlich, K. Bobacz, G. Kollias, J. S. Smolen, G. Schett, Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum. 54, 463-472 (2006).
30. I.Matsumoto, H. Zhang, T. Yasukochi, K. Iwanami, Y. Tanaka, A. Inoue, D. Goto, S. Ito, A. Tsutsumi, T. Sumida, Therapeutic effects of antibodies to tumor necrosis factor-A, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res. Ther. 10, R66 (2008).
31. H. Ji, A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, C. Benoist, Critical roles for interleukin 1 and tumor necrosis factor a in antibody-induced arthritis. J. Exp. Med. 196, 77-85 (2002).
32. M. Marenzana, A. Vugler, A. Moore, M. Robinson, Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: A microCT study. Arthritis Res. Ther. 15, R125 (2013).
33. M. Lewis, L. A. Tartaglia, A. Lee, G. L. Bennett, G. C. Rice, G. H.W.Wong, E. Y. Chen, D. V. Goeddel, Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. U.S.A. 88, 2830-2834 (1991).
34. M. van Dinther, J. Zhang, S. E. Weidauer, V. Boschert, E.-M. Muth, A. Knappik, D. J. J. de Gorter, P. B. van Kasteren, C. Frisch, T. D. Mueller, P. ten Dijke, Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLOS One 8, e62295 (2013).
35. N. C. Walsh, E. M. Gravallese, Bone loss in inflammatory arthritis: Mechanisms and treatment strategies. Curr. Opin. Rheumatol. 16, 419-427 (2004).
36. K. Ishihara, T. Hirano, IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13, 357-368 (2002).
37. A. R. Moschen, A. Kaser, B. Enrich, O. Ludwiczek, M. Gabriel, P. Obrist, A. M. Wolf, The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54, 479-487 (2005).
38. P. N. Sambrook, The skeleton in rheumatoid arthritis: Common mechanisms for bone erosion and osteoporosis? J. Rheumatol. 27, 2541-2542 (2000).
39. A. K. S. Gough, P. Emery, R. L. Holder, J. Lilley, S. Eyre, Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344, 23-27 (1994).
40. X.-X. Chen, W. Baum, D. Dwyer, M. Stock, K. Schwabe, H.-Z. Ke, M. Stolina, G. Schett, A. Bozec, Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann. Rheum. Dis. 72, 1732-1736 (2013).
41. B. Y. Chan, E. S. Fuller, A. K. Russell, S. M.Smith, M. M. Smith, M. T. Jackson, M. A. Cake, R. A. Read, J. F. Bateman, P. N. Sambrook, C. B. Little, Increased chondrocyte sclerostinmay protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage 19, 874-885 (2011).
42. W. Bouaziz, T. Funck-Brentano, H. Lin, C. Marty, H.-K. Ea, E. Hay, M. Cohen-Solal,Loss of sclerostin promotes osteoarthritis in mice via b-catenin-dependent and-independent Wnt pathways. Arthritis Res. Ther. 17, 24 (2015).
43. M. Roudier, X. Li, Q.-T. Niu, E. Pacheco, J. K. Pretorius, K. Graham, B.-R. P. Yoon, J. Gong, K. Warmington, H. Z. Ke, R. A. Black, J. Hulme, P. Babij, Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum. 65, 721-731 (2013).
44. K. Baek, H. R. Hwang, H.-J. Park, A. Kwon, A. S. Qadir, S.-H. Ko, K. M. Woo, H.-M. Ryoo, G.-S. Kim, J.-H. Baek, TNF-A upregulates sclerostin expression in obese mice fed a high-fat diet. J. Cell. Physiol. 229, 640-650 (2014).
45. B.-J. Kim, S. J. Bae, S.-Y. Lee, Y.-S. Lee, J.-E. Baek, S.-Y. Park, S. H. Lee, J.-M. Koh, G. S. Kim, TNF-A mediates the stimulation of sclerostin expression in an estrogen-deficient condition. Biochem. Biophys. Res. Commun. 424, 170-175 (2012).
46. S. Ren, B. G. Johnson, Y. Kida, C. Ip, K. C. Davidson, S.-L. Lin, A. Kobayashi, R. A. Lang, A.-K. Hadjantonakis, R. T. Moon, J. S. Duffield, LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc. Natl. Acad. Sci. U.S.A. 110, 1440-1445 (2013).
47. I. ?ervenka, J. Wolf, J. Ma͉ek, P. Krejci, W. R. Wilcox,A. Kozubík,G. Schulte, J. S. Gutkind, V. Bryja, Mitogen-Activated protein kinases promote WNT/b-catenin signaling via phosphorylation of LRP6. Mol. Cell Biol. 31, 179-189 (2011).
48. O. Frey, A. Reichel, K. Bonhagen, L. Morawietz, U. Rauchhaus, T. Kamradt, Regulatory T cells control the transition from acute into chronic inflammation in glucose-6-phosphate isomeraseinduced arthritis. Ann. Rheum. Dis. 69, 1511-1518 (2010).
49. P. A.Monach, D.Mathis, C. Benoist, The K/BxN arthritismodel. Curr. Protoc. Immunol. Chapter 15, Unit 15.22 (2008).
50. J. Seibler, B. Zevnik, B. Küter-Luks, S. Andreas, H. Kern, T. Hennek, A. Rode, C. Heimann, N. Faust, G. Kauselmann, M. Schoor, R. Jaenisch, K. Rajewsky, R. Kühn, F. Schwenk, Rapid generation of inducible mouse mutants. Nucleic Acids Res. 31, e12 (2003).
51. J. Huelsken, R. Vogel, B. Erdmann, G. Cotsarelis, W. Birchmeier, b-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105, 533-545 (2001).
52. M. Hoberg, M. Rudert, T. Pap, G. Klein, S. Gay, W. K. Aicher, Attachment to laminin-111 facilitates transforming growth factor b-induced expression of matrix metalloproteinase-3 in synovial fibroblasts. Ann. Rheum. Dis. 66, 446-451 (2007).